test

Patient & Cancer Information | Clinical Trials | Available Trials | Trial

HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer

Conditions

Advanced Breast Cancer

What is the purpose of this trial?

The purpose of this study is to determine the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), of oral vorinostat in combination with oral capecitabine given on days 1-7 and 15-21 of a 28 day cycle in patients with advanced breast cancer, using RECIST criteria.


Participation Guidelines

Age:
18 Years and older
Gender:
Female

Click here for detailed information about who can participate in this trial.

Sponsor:
Merck
Yale University
Dates:
December 2008
Last Updated:
Oct 08, 2009
Study HIC#:
0803003591

Clinicaltrials.gov ID: NCT00719875